Preview

Eurasian heart journal

Advanced search

Cardiovascular diseases in patients with psoriasis in clinical practice: case report. Eurasian heart journal

https://doi.org/10.38109/2225-1685-2022-1-94-99

Abstract

Psoriasis is a genetically determined multifactorial disease that affects about 2% of the population. According to modern concepts of this disease, the level of comorbid diseases, especially those associated with damage to the cardiovascular system, is high. This article presents a clinical case of severe disseminated psoriasis vulgaris, progressive stage, mixed form in a patient with a very high cardiovascular risk. The uniqueness of this clinical case lies in the combined course of psoriasis and such comorbid diseases as: severe hypertension, obesity, dyslipidemia, type 2 diabetes mellitus (DM), hyperuricemia. The main clinical manifestations were the presence of widespread lesions on the patient’s skin, episodes of discomfort behind the sternum during physical activity, as well as destabilization of blood pressure numbers (maximum rise to 180/100 mm Hg). As part of the hospitalization in the skin clinic, the patient underwent topical ointment therapy with the use of glucocorticoid ointments, ointments containing salicylic acid, PUVA therapy, as a result of which the skin process showed positive dynamics with regression of lesions by 90-100% with an outcome in residual hyperpigmentation, no new lesions were noted. During hospitalization to a therapy department, the optimal antihypertensive, lipid-lowering, uricosuric, hypoglycemic therapy was selected, as a result of which it was possible to achieve an improvement in the patient’s condition, stabilization of blood pressure at the level of 130-140/70 mm Hg. So patients with psoriasis require careful assessment of cardiovascular risk in clinical practice. A multidisciplinary approach will not only improve the quality of life of patients, reduce the likelihood of major cardiovascular events, but also increase life expectancy and reduce mortality.

About the Authors

O. A. Kuzmina
Sechenov First Moscow State Medical University (Sechenov University)
Russian Federation

 Olga A. Kuzmina, postgraduate student of the Department of Faculty Therapy No. 1, N.V. Sklifosovsky Institute of Clinical
Medicine

 tel.: 8(499) 248-64-79 

 8, building 2, Trubetskaya st., Moscow, 119991 



O. Iu. Mironova
Sechenov First Moscow State Medical University (Sechenov University)
Russian Federation

  Olga Iu. Mironova, Cand. of Sci. (Med.), Associate Professor of the Department of Faculty Therapy No. 1, N.V. Sklifosovsky Institute of Clinical Medicine 

8, building 2, Trubetskaya st., Moscow, 119991 



V. V. Fomin
Sechenov First Moscow State Medical University (Sechenov University)
Russian Federation

  Viktor V. Fomin, corresponding member of RAS, Dr. of Sci. (Med.), Prof., Vice-Rector for Innovation and Clinical Activities, Head of the Department of Faculty Therapy No. 1, N.V. Sklifosovsky Institute of Clinical Medicine 

8, building 2, Trubetskaya st., Moscow, 119991 



References

1. Miller IM, Ellervik C, Yazdanyar S, et al. Meta-analysis of psoriasis, cardiovascular disease, and associated risk factors. Journal of the American Academy of Dermatology 2013; 69:1014–1024, https://doi.org/10.1016/J.JAAD.2013.06.053

2. Parisi R, Iskandar IYK, Kontopantelis E, et al. National, regional, and worldwide epidemiology of psoriasis: systematic analysis and modelling study on behalf of the Global Psoriasis Atlas. BMJ 2020;369:m1590, https://doi.org/10.1136/bmj.m1590

3. Kim WB, Jerome D, Yeung J. Diagnosis and management of psoriasis. Canadian Family Physician 2017; 63: 278–285.

4. Takeshita J, Grewal S, Langan SM, et al. Psoriasis and comorbid diseases: Epidemiology. Journal of the American Academy of Dermatology 2017; 76:377–390, https://doi.org/10.1016/J.JAAD.2016.07.064

5. Rendon A, Schäkel K. Psoriasis Pathogenesis and Treatment. International Journal of Molecular Sciences 2019; 20:1475, https://doi.org/10.3390/ijms20061475

6. Nehring P, Przybyłkowski A. Is Psoriasis Treatment a Risk Factor for Inflammatory Bowel Disease? Pharmaceutical Medicine 2020; 34:257–262, https://doi.org/10.1007/s40290-020-00340-1

7. Abramczyk R, Queller JN, Rachfal AW, et al. Diabetes and Psoriasis: Different Sides of the Same Prism. DMSO 2020:13 3571–3577, https://doi.org/10.2147/DMSO.S273147

8. Zhong S, Li L, Shen X, et al. An update on lipid oxidation and inflammation in cardiovascular diseases. Free Radical Biology and Medicine 2019; 144:266–278, https://doi.org/10.1016/J.FREERADBIOMED.2019.03.036

9. Weber B, Merola JF, Husni ME, et al. Psoriasis and Cardiovascular Disease: Novel Mechanisms and Evolving Therapeutics. Current Atherosclerosis Reports 2021; 23:67, https://doi.org/10.1007/s11883-021-00963-y

10. Armstrong EJ, Harskamp CT, Armstrong AW. Psoriasis and Major Adverse Cardiovascular Events: A Systematic Review and MetaAnalysis of Observational Studies, Journal of the American Heart Association, 2013;2:e000062, https://doi.org/10.1161/JAHA.113.000062

11. Takeshita J, Grewal S, Langan M, et al. Psoriasis and comorbid diseases Implications for management. Journal of American Dermatology 2017; 76:393–403, https://doi.org/10.1016/j.jaad.2016.07.065

12. Masson Martín Lobo Graciela Molinero W. Psoriasis and Cardiovascular Risk: A Comprehensive Review. https://doi.org/10.6084/m9.figshare.12091383

13. Langley RG, Ellis CN. Evaluating psoriasis with Psoriasis Area and Severity Index, Psoriasis Global Assessment, and Lattice System Physician’s Global Assessment. Journal of the American Academy of Dermatology 2004; 51:563–569, https://doi.org/10.1016/j.jaad.2004.04.012

14. Golbari NM, Porter ML, Kimball AB. Current guidelines for psoriasis treatment: A work in progress. Cutis 2018; 101:10–12.

15. Wollina U, Tirant M, Vojvodic A, et al. Treatment of Psoriasis: Novel Approaches to Topical Delivery the Creative Commons AttributionNonCommercial 4.0 International License (CC BY-NC 4.0). Global Dermatology Open Access Maced J Med Sci 2019; 7:3018–3025 https://doi.org/10.3889/oamjms.2019.414

16. Клинические рекомендации по ведению больных псориазом. Общероссийская общественная организация «Российское общество дерматовенерологов и косметологов», 2019 [Clinical guidelines for the management of patients with psoriasis. All-Russian Public Organization «Russian Society of Dermatovenereologists and Cosmetologists», 2019 (in Russ.)], https://www.rodv.ru/upload/iblock/aa2/aa20a2fc65b13df3899140167777092d.pdf

17. Korman N, Korman N, Squibb B-M, et al. Management of psoriasis as a systemic disease: what is the evidence? Funding sources Conflicts of interest. British Journal of Dermatology Linked Comment: Gisondi Br J Dermatol 2020; 182:823–824, https://doi.org/10.1111/bjd.18245

18. Nast A, Amelunxen L, Augustin M, et al. S3 Guideline for the treatment of psoriasis vulgaris, update - Short version part 1 - Systemic treatment. JDDG - Journal of the German Society of Dermatology 2018; 16:645–670, https://doi.org/10.1111/ddg.13516

19. Ridker PM, Danielson E, Fonseca FAH, et al. Rosuvastatin to Prevent Vascular Events in Men and Women with Elevated C-Reactive Protein. New England Journal of Medicine 2008; 359:2195–2207, https://doi.org/10.1056/NEJMoa0807646

20. Garshick MS, Drenkova K, Barrett TJ, et al. A Randomized Open Label Clinical Trial of Lipid-Lowering Therapy in Psoriasis to Reduce Vascular Endothelial Inflammation. Journal of Investigative Dermatology; 0. Epub ahead of print November 2021, https://doi.org/10.1016/J.JID.2021.07.190

21. Garshick MS, Ward NL, Krueger JG, et al. Cardiovascular Risk in Patients With Psoriasis: JACC Review Topic of the Week. Journal of the American College of Cardiology 2021; 77:1670–1680, https://doi.org/10.1016/j.jacc.2021.02.009

22. Mofarrah R, Mofarrah R, Amiri KJ. Beta-blocker bisoprolol induced psoriasis. Our Dermatology Online 2020; 11:59–61, https://doi.org/10.7241/ourd.20201.15

23. Milavec-Puretić V, Mance M, Čeović R, et al. Drug-Induced Psoriasis. American Journal of Clinical Dermatology 2012; 1:159–165, https://doi.org/10.2165/00128071-200001030-00003

24. Balak DM, Hajdarbegovic E. Drug-induced psoriasis: clinical perspectives. Psoriasis (Auckland, NZ) 2017; 7:87–94, https://doi.org/10.2147/PTT.S126727

25. Puig L. Molecular Sciences Cardiometabolic Comorbidities in Psoriasis and Psoriatic Arthritis. Int. J. Mol. Sci. 2018, 19(1):58, https://doi.org/10.3390/ijms19010058

26. Burns DM. Epidemiology of smoking-induced cardiovascular disease. Progress in Cardiovascular Diseases 2003; 46:11–29, https://doi.org/10.1016/S0033-0620(03)00079-3

27. Pezzolo E, Naldi L. The relationship between smoking, psoriasis and psoriatic arthritis. Expert Review of Clinical Immunology 2019; 15:41–48, https://doi.org/10.1080/1744666X.2019.1543591

28. Madden SK, Flanagan KL, Jones G. How lifestyle factors and their associated pathogenetic mechanisms impact psoriasis. Clinical Nutrition 2020; 39:1026–1040, https://doi.org/10.1016/j.clnu.2019.05.006

29. Norden A, Rekhtman S, Strunk A, et al. Risk of psoriasis according to body mass index: A retrospective cohort analysis. Journal of the American Academy of Dermatology 2021; 1–7, https://doi.org/10.1016/j.jaad.2021.06.012

30. Aune D, Schlesinger S, Norat T, et al. Tobacco smoking and the risk of heart failure: A systematic review and meta-analysis of prospective studies. European Journal of Preventive Cardiology 2019; 26:279–288, https://doi.org/10.1177/2047487318806658

31. Brazzelli V, Maffioli P, Bolcato V, et al. Psoriasis and Diabetes, a Dangerous Association: Evaluation of Insulin Resistance, Lipid Abnormalities, and Cardiovascular Risk Biomarkers. Frontiers in Medicine 2021; 8: 1–7, https://doi.org/10.3389/fmed.2021.605691

32. Aleem D, Tohid H. Pro-inflammatory Cytokines, Biomarkers, Genetics and the Immune System: A Mechanistic Approach of Depression and Psoriasis. Revista Colombiana de Psiquiatría 2018; 47:177–186,https://doi.org/10.1016/j.rcp.2017.03.002

33. Collaboration S working group and EC risk, Achenbach S, Aleksandrova K, et al. SCORE2 risk prediction algorithms: new models to estimate 10-year risk of cardiovascular disease in Europe. European Heart Journal 2021; Advance Article: 1–1, https://doi.org/10.1093/eurheartj/ehab309

34. Lloyd-Jones DM, Wilson PWF, Larson MG, et al. Framingham risk score and prediction of lifetime risk for coronary heart disease. The American journal of cardiology 2004; 94: 20–24, https://doi.org/10.1016/j.amjcard.2004.03.023

35. Baeta IGR, Gontijo B, Bittencourt FV, et al. Comorbidities and cardiovascular risk factors in patients with psoriasis. Anais Brasileiros de Dermatologia 2014; 89: 735–744, https://doi.org/10.1590/ABD1806-4841.20142874

36. Barbieri JS, Beidas RS, Gondo GC, et al. Analysis of Specialist and Patient Perspectives on Strategies to Improve Cardiovascular Disease Prevention Among Persons With Psoriatic Disease. JAMA Dermatology; 158. Epub ahead of print March 19, 2022, https://doi.org/10.1001/jamadermatol.2021.4467

37. Garshick MS, Berger JS. Psoriasis and Cardiovascular Disease—An Ounce of Prevention Is Worth a Pound of Cure. JAMA Dermatology; 158. Epub ahead of print March 19, 2022, https://doi.org/10.1001/jamadermatol.2021.4723


Review

For citations:


Kuzmina O.A., Mironova O.I., Fomin V.V. Cardiovascular diseases in patients with psoriasis in clinical practice: case report. Eurasian heart journal. Eurasian heart journal. 2022;(1):94-99. (In Russ.) https://doi.org/10.38109/2225-1685-2022-1-94-99

Views: 1127


ISSN 2225-1685 (Print)
ISSN 2305-0748 (Online)